In this prospective study we analyzed pre-emptive donor leukocyte infusions (DLI) in 82 consecutive patients transplanted with partially T cell-depleted grafts for acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation and multiple myeloma. Donors were HLA-identical siblings. Patients without significant acute (Ͼgrade 1) and/or chronic GVHD were scheduled to be treated with DLI (35 patients) and 31 actually received DLI. Patients who developed acute GVHD Ͼgrade 1 and/or chronic GVHD were not scheduled to receive DLI and served as a comparison group (47 patients). The median interval between BMT and DLI was 22 weeks. The first six patients received 0.7 × 10 8 CD3
Introduction
Allogeneic bone marrow transplantation (BMT) has become the treatment of choice for acute and chronic leukemias. [1] [2] [3] [4] [5] [6] [7] [8] [9] Outcome and success of BMT has been limited by post-transplant complications such as graft failure, graft-versus-host disease (GVHD), and relapse of the original disease. Moderate to severe GVHD occurs in about 30% to 70% of HLA matched recipients and contributes to death in 20% to 70% of those affected. 4, 10 The incidence and severity of acute GVHD can be reduced by removal of immunocompetent T lymphocytes from the graft using different techniques. 11 T cell depletion, however, is associated with increased incidence of graft rejection and leukemic recurrence. 3, [12] [13] [14] Relapse rates are depen- dent on the number of residual tumor cells after conditioning for BMT and the number of immunocompetent donor lymphocytes after transplantation that may exert graft-versus-leukemia (GVL) reactivity. The association between GVHD and GVL reactivity has been documented in several clinical trials. 15, 16 We showed that intensification of the conditioning regimen in patients transplanted for acute and chronic leukemias with grafts partially depleted of lymphocytes significantly decreased the relapse rate and significantly increased leukemia-free survival (LFS). 17 Relapse rates varied from 20 to 32% which was still considered high.
Both animal and human experimental data support the hypothesis that GVL reactivity can be generated by post-transplant infusion of donor leukocytes while GVHD is controlled. The risk of acute GVHD after DLI depends on the number of lymphocytes infused and the time interval between BMT and DLI. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Additional add-back of donor lymphocytes shortly after transplantation resulted in severe GVHD. 28 Delayed donor leukocyte infusions (DLI) with T cell doses of 10 5 -10 7 /kg resulted in less severe GVHD varying in incidence from 42 to 53% in these patients. 29 In the present study, we analyzed the influence of preemptive DLI on relapse rate, survival, disease-free survival and chimerism in patients who were at high risk for relapse and who did not suffer from significant acute nor chronic GVHD after partially T cell-depleted BMT. We compared results with those obtained in patients who were transplanted in the same period but who were excluded from pre-emptive DLI because they had significant GVHD.
Patients and methods

Patient characteristics
A total of 82 consecutive patients who underwent allogeneic bone marrow transplantation at the University Medical Center St Radboud Nijmegen between May 1995 and June 1999 were included in this prospective non-randomized study. Patients were transplanted for acute myeloid leukemia (AML) (n = 28), acute lymphoid leukemia (ALL) (n = 10), chronic myeloid leukemia (CML) (n = 27), refractory anemia with excess of blasts (RAEB) (n = 3), refractory anemia with excess of blasts in transformation (RAEB-t) (n = 4) and multiple myeloma (MM) (n = 10). Patients who died from treatment-related causes within 3 months after BMT were excluded from the study. Donors were HLA A, B, DRB and DQB identical siblings. Patients were eligible for pre-emptive DLI if they fulfilled all three of the following criteria: (1) They had not suffered from acute GVHD greater than grade one; (2) they had no persisting chronic GVHD; (3) all additional immunosuppression given for prophylaxis of GVHD had been withdrawn for a minimum of 2 months without developing any symptoms of GVHD. Patients who had GVHD greater than grade 1 and/or chronic GVHD were not eligible for DLI and served as a comparison group. Informed consent was obtained from each patient (or their guardians) and all treatment was administered under protocols approved by the local ethical committee of the University Medical Center St Radboud Nijmegen. Clinical characteristics of the 82 patients included in this study are listed in Table 1 . Thirty-five patients did not develop significant GVHD after BMT and were eligible for DLI. Sixteen out of these 35 patients (46%) had bad risk prognostic factors. Six patients were transplanted for MM in partial remission (PR), two patients had accelerated CML, four patients had RAEB(-t) from which two still had cytogenetic abnormalities (deletion of chromosome 7) at the time of BMT. One patient had ALL in second complete remission (CR) and one patient had AML in second complete remission with cytogenetic abnormalities at BMT (5q−). One patient was transplanted for AML in partial remission and another patient needed two remission induction courses to enter first CR and had residual cytogenetic abnormalities (11q−) at the time of BMT.
Two patients transplanted for AML relapsed before they were eligible for DLI and two patients with MM showed rapid progressive disease before DLI was given. These patients were included in the DLI group on the basis of intention-to-treat. Thirty-one patients actually received DLI.
Forty-seven patients developed acute GVHD Ͼgrade 1 and/or chronic GVHD and were included in the non-DLI group. In this non-DLI group, 13 patients (28%) had additional bad risk prognostic factors. Four patients were transplanted for MM in partial remission, three patients had AML in second CR, three patients had RAEB(t), two patients had accelerated CML and one patient received BMT for ALL in second CR. In the non-DLI group there were no patients who had residual cytogenetic abnormalities detected at time of transplantation.
Although not significant, the non-DLI group contained a relatively higher number of patients transplanted for ALL in first CR (Table 1 ). None of the ALL patients was Philadelphia chromosome positive at the time of diagnosis. The numbers of patients with bad risk prognostic factors were not significantly different between the two groups.
Conditioning regimen, GVHD prophylaxis and supportive care
Seventy-nine out of 82 patients were conditioned with idarubicine 42 mg/m 2 by continuous intravenous (i.v.) infusion on days −12 and −11 followed by cyclophosphamide 60 mg/kg b.w. i.v. on each of 2 consecutive days (days −6 and −5). Fractionated total body irradiation (TBI) was given on days −2 and −1 to a total dose of 9 Gy. In three patients TBI was substituted by busulphan 4 mg/kg b.w. on each of 4 consecutive days (day −8 to day −5). Donor marrow was depleted of lymphocytes by density gradient centrifugation followed by counterflow centrifugation as previously described. 30, 31 The median number of T cells in the marrow grafts was 0.7 (range, 0.6-1.5) × 10 6 CD3 + cells/kg b.w. All patients received prophylactic antibiotics according to institutional guidelines. Immunoprophylaxis after transplant consisted of cyclosporin A (CsA) 3 mg/kg/day by continuous i.v. infusion from days −1 to +14, followed by 2 mg/kg/day as a continuous i.v. infusion until day 21. Beyond day 21, CsA was administered orally at a dose of 6 mg/kg/day until 8 to 10 weeks after BMT. In the absence of GVHD CsA was gradually tapered and discontinued at 12 weeks post-grafting. All patients were managed in single rooms with filtered air under positive pressure during their hospital stay.
Assessment of GVHD, relapse and chimerism
Acute GVHD was classified from grade 0 to 4 according to the criteria described by Glucksberg et al. 32 Chronic GVHD was graded as none, limited or extensive. 33 Acute GVHD after pre-emptive DLI was defined as GVHD occurring within 100 days from infusion. Chronic GVHD after DLI was defined as GVHD present after day 100 from infusion. Relapse was defined as hematologic and/or cytogenetic relapse. Durable engraftment and chimerism was investigated by cytogenetic analysis of blood and bone marrow and/or by red blood cell phenotyping. Chromosome studies on peripheral blood cells and bone marrow cells were performed routinely before BMT, 6 and 12 months after BMT and annually thereafter as described previously. 34, 35 The median number of bone marrow metaphases analyzed was 30 (range, , and the median number of metaphases of lymphocytes was 32 (range, 7-32), allowing a sensitivity level of 10-12%. 36 When the recipient and donor were of different sex, heterosome determination of 400 interphases (fluorescent in situ hybridization; FISH) allowed additional differentiation between donor and host cells, resulting in a sensitivity of 1% for the demonstration of a minor cell population. After DLI, these chromosome stud-ies were performed on bone marrow at 3, 6 and 12 months and annually thereafter. Red blood cell phenotyping was performed using a flow cytometric and/or fluorescent microscopic microsphere method as described previously. [37] [38] [39] The sensitivity level is 0.1-0.3% for the flow cytometric method and 0.01% for the fluorescent microscopic technique. At the level of 0% patient or donor red cells, the flow cytometric results were always controlled by the fluorescent microscopic method in order to increase the sensitivity of this test to a level of 0.01% in this analysis. The time schedule for analysis was 1, 2, 3, 6 and 12 months after BMT and annually thereafter. The same intervals were used after DLI.
DLI
Donor leukocytes were obtained from the original bone marrow donor by leukapheresis using the blood cell separator Baxter CS 3000 (Baxter, Deerfield, IL, USA) or the Fresenius AS 104 (Oberursel, Germany) as previously described. /kg body weight, respectively. The interval between BMT and preemptive DLI was a median of 22 weeks (range, . No GVHD prophylaxis was administered to any of the patients after the infusion of the donor lymphocytes.
Statistics
Patient, disease and graft-versus-host characteristics were compared between groups with the Wilcoxon signed rank test and Fisher's exact test using the Statistica 4.5 release program for MS Windows (Statsoft). The Kaplan-Meier product limit method 41 was used to estimate the rate of relapse, diseasefree survival (DFS), and overall survival. The two-tailed logrank test was used to compare the clinical endpoints between the two groups. Endpoints were calculated at the date of last follow-up being 1 August 2000. The duration of follow-up since BMT in the DLI group and control group was a median of 30 (range, 14-66) and 26 (range, 13-62) months, respectively (P = 0.63).
Results
Graft-versus-host disease after BMT
Thirty-five patients had grade 0 or grade 1 acute GVHD without any signs of chronic GVHD (Table 1) . They were included in the DLI group on the basis of intention-to-treat. The 10 patients who developed grade 1 acute GVHD were not treated with additional systemic steroids. The interval between date Leukemia of BMT and date of withdrawing CsA was a median of 3.5 months (range, 2-7) in these 35 patients.
Twenty-one patients developed grade 2 acute GVHD and consequently were included in the non-DLI group (Table 1) . Eleven out of these 21 patients showed progression to chronic GVHD (limited: n = 9, extensive: n = 2). Three patients had grade 3 acute GVHD after BMT and two of them developed chronic GVHD (extensive: n = 2). Two patients had grade 4 acute GVHD and both progressed to extensive chronic GVHD. Twenty-one patients were included in the non-DLI group because they developed chronic GVHD (limited: n = 19, extensive: n = 2) without pre-existent significant (Ͼgrade 1) acute GVHD. Thirty-seven out of 47 patients in the non-DLI group (79%) received additional systemic steroids as GVHD treatment. The median interval between BMT date and cessation of all immunosuppressive drugs in the non-DLI group was 4 months (range, 2-22).
Graft-versus-host-disease after DLI
The first six patients treated with pre-emptive DLI received a T cell dose of 0. + cells infused resulted in less frequent (P = 0.059, Fisher's exact) and less severe acute GVHD and consequently hardly any chronic GVHD. The interval between DLI and onset of acute GVHD in the 13 patients was a median of 7 weeks (range, 2-9). Twelve out of 13 patients with acute GVHD after DLI were treated with immunosuppressive drugs. CsA was given in seven patients and CsA plus systemic steroids were given to five patients. The median duration of this immunosuppressive therapy was 4 months (range, 2-31).
In Table 2 GVHD after DLI is related to GVHD after BMT. One of the seven patients who had grade 1 acute GVHD after BMT developed acute GVHD grade 1 after DLI and another patient developed acute GVHD grade 3 after DLI. These two patients also developed limited chronic GVHD. Five patients Table 2 The incidence of graft-versus-host disease after donor lymphocyte infusion in relation to the incidence of GVHD after BMT in 31 patients GVHD after DLI
The percentage is expressed as the number of patients with or without GVHD after DLI divided by the number of patients with GVHD and without GVHD after BMT, respectively.
with grade 1 acute GVHD after BMT did not develop GVHD after DLI. Eleven patients who initially had no GVHD after BMT, developed acute GVHD after DLI (grade 1: n = 6, grade 2: n = 3, grade 3: n = 1 and grade 4: n = 1). Only three patients developed chronic GVHD (limited: n = 2, extensive: n = 1). Thirteen patients did not have GVHD at all, either after BMT or after DLI. The incidence of GVHD after BMT did not correlate with the incidence of GVHD after DLI (Spearman rank order test P = 0.17).
Mortality
Seven out of 35 patients (20%) in the DLI group have died at the end of follow-up. Four patients (11%) relapsed or had progressive disease before they were eligible for DLI (AML: n = 2, MM: n = 2). One patient relapsed from RAEB 34 months after pre-emptive DLI and did not respond to escalating doses DLI. He was then retransplanted and died 3 months after second BMT of severe GVHD. Another patient died from severe GVHD following pre-emptive DLI and a third patient died 9 months after DLI from cerebral hemorrhage without any signs of relapse. In the non-DLI group 17 out 47 patients (36%) died, 12 died from relapse (AML: n = 2, ALL: n = 2, CML: n = 4, RAEB(-t): n = 2, MM: n =2) and five patients died from GVHD (AML: n = 3, ALL: n = 1, CML: n = 1). Overall mortality was lower in the DLI group although not significant (P = 0.14). Treatment-related mortality (ie mortality while in continuous complete remission) did not differ between the two groups (P = 0.36).
Relapse
From the 35 patients who were included in the DLI group, four patients (AML n = 2, MM: n = 2) relapsed or had progressive disease at 2, 5, 7 and 8 months after BMT, respectively, and before they were eligible for DLI. Only three (AML-CR1, ALL-CR2 and RAEB) out of 31 patients who actually received DLI relapsed at 7, 11 and 41 months after BMT and at 1, 5 and 35 months after DLI, respectively. In the non-DLI group, 19 out of 47 patients relapsed from their original disease (CML-CP1: n = 8, CML in acceleration: n = 2, AML: n = 2, ALL: n = 2, MM: n = 3, RAEB: n = 1, RAEB-t: n = 1) at a median of 11 months (range, 5-22) after BMT. The projected 3-year probability of relapse for all 35 patients in the DLI group was 18% (95% CI, 5-31%). This was significantly lower than the projected 3-year probability of relapse of 44% (95% CI, 28-60%) for patients in the non-DLI group (P = 0.026) as shown in Figure 1a . The four patients who relapsed before they were eligible for pre-emptive DLI were all therapeutically treated with highdose DLI (1 × 10 8 CD3 + cells/kg b.w.) but all died of progressive disease. Two out of three patients who relapsed after preemptive DLI did not respond to repetitive higher doses of DLI and died of progressive disease (ALL-CR2) and because of severe GVHD after a second BMT (RAEB), respectively. The patient who relapsed from AML had only cytogenetic relapse and was in continuous hematologic remission with normal peripheral blood counts at the end of follow-up. All 19 patients who relapsed in the non-DLI group were treated with high-dose DLI (0.7 × 10 8 /kg b.w.). Five out of eight patients with CML in first chronic phase responded and are currently free of leukemia. Two patients in the non-DLI group with MM showed partial response to high-dose DLI. However, this Probability of relapse, survival and leukemia-free survival. Probability of relapse (a), survival (b) and leukemia-free survival (c) in patients who were included in the DLI group on the basis of intention to treat and patients included in the non-DLI group. Symbols in the curves denote patients who are alive (b) or leukemia-free survivors (a, c).
response was only temporary (3 and 4 months, respectively) and both patients died from progressive disease. All other 12 patients did not respond to high-dose therapeutic DLI and died from relapse.
Survival
In the DLI group, 28 of 35 patients (80%) are alive at a median of 30 months (range, 14-65 months) after BMT. In the non-DLI group, 30 out of 47 patients (64%) are alive at a median of 26 months (range, 13-62 months) after BMT. The projected 3-year probability of survival in the patients included in the DLI group was 79% (95% CI, 63-95%). Although there is a trend, this is not yet significantly better than the 63% (95% CI, 47-79%) obtained in the patients not treated with preemptive DLI (P = 0.07) (Figure 1b) .
Leukemia-free survival
The projected 3-year probability of leukemia-free survival in the patients included in the DLI group was 77% (95% CI, 63-91%), which is significantly better compared to the projected 3-year probability of LFS of 51% (95% CI, 36-66%) of the patients in the non-DLI group (P = 0.024) (Figure 1c) . If we consider the five patients with relapsed CML and who responded to therapeutic DLI as patients who are in current leukemia-free survival the projected 3-year probability of LFS in the non-DLI group is 60% (95% CI, 45-75%) (P = 0.14).
Hematopoietic chimerism
Hematopoietic chimerism was assessed at regular intervals after BMT and DLI. In the 35 patients who were included in the DLI group, 18 patients (51%) had complete donor chimerism at the time of DLI. The median time from BMT onwards to the establishment of complete donor chimerism in these patients was 5 months (range, 3-9 months). Nine patients (26%) had mixed chimeras at the time of DLI and in these patients the majority of cells was usually of donor origin (median 98%, range 17-99%). The interval between DLI and the conversion to complete donor chimerism was a median of 3 months (range, 3-6) in seven evaluable patients. One patient died of GVHD before chimerism was evaluated and one patient has stable mixed chimerism with predominantly autologous cells (98%) but without any sign of relapse of the original disease. Four patients relapsed before DLI. These four patients never reached complete donor chimerism after BMT. Another four patients had no informative marker to evaluate chimerism.
In the non-DLI group, 37 out of 47 patients (78%) had complete donor chimerism at a median of 3 months (range, 3-9) after BMT. Eight patients who had complete donor chimerism regained autologous cells and relapsed of their disease. Three out of these eight patients responded to high-dose DLI and are in current complete remission with 100% donor chimerism. Five patients (11%) had persisting autologous cells after BMT and relapsed. Two out of these five patients responded to high-dose DLI with the development of complete donor chimerism and remission of the underlying disease. One patient is alive without responding to DLI and with stable disease and two patients died of relapse. Five patients in the non-DLI group (11%) did not have a discriminating marker.
Considering all patients who developed complete donor chimerism after BMT, the patients in the non-DLI group developed significantly earlier complete donor chimerism compared to the patients in the DLI group, a median of 3 vs 6 months, respectively (P = 0.02).
Discussion
We observed that pre-emptive DLI in patients who were at high risk for relapse after partially T cell-depleted BMT was associated with a relatively low probability of relapse. Despite the lower incidence of GVHD in the DLI group, the probability of relapse in this group was significantly lower comLeukemia pared to the probability of relapse of the patients who were included in the non-DLI group. Previous studies in murine models and in BMT patients who relapsed from their original disease show a dose-and time-dependent probability of developing GVHD after DLI. These studies also show the possibility of a graft-versus-leukemia effect that is not associated with GVHD. 28, [42] [43] [44] [45] Only a few studies report on the preemptive administration of DLI after T cell-depleted BMT. 29, 46 In the study by Naparstek et al DLI was given in escalating doses starting immediately after BMT. 29 However, this resulted in clinically significant GVHD and no significant benefit on the overall probability of relapse. In the study by Barrett et al, escalating DLI were given within the first 3 months after BMT during CsA immunosuppression. 19 GVHD incidence and severity were low but beneficial influence on relapse and leukemia-free survival could not be demonstrated. In our study, in the majority of patients, we selectively administered a single, relatively low and fixed dose of 0.1 × 10 8 CD3 + donor lymphocytes/kg b.w. at median 22 weeks after BMT in patients who had no significant GVHD after withdrawing all immunosuppressive therapy. Only a minority of patients (42%) developed GVHD after DLI. However, the first six patients in this study, who were treated with a higher dose of 0.7 × 10 8 CD3 + cells/kg b.w., developed GVHD more frequently and more severely than we had anticipated. GVHD in one patient did not respond to intensive immunosuppression and this patient died from complications of GVHD. After treating the first six patients with pre-emptive DLI we decided to decrease the CD3 + cell content of the mononuclear cells infused to 0.1 × 10 8 /kg b.w. The patients who received the lower dose CD3
+ cells in the DLI developed mild GVHD, which did not contribute to severe morbidity or mortality. These observations of a dose-and time-dependent probability of developing GVHD after DLI are concordant with the data from previous studies. 19, [43] [44] [45] The interval between DLI (median 7 weeks) and onset of GVHD did not differ between patients who were treated with a higher dose of DLI for relapse of their original disease and the patients in this study who received pre-emptive DLI. 46 Fifty-eight percent of the patients in the DLI group did not develop any GVHD after lymphocyte infusion. It is probable in these patients that GVL reactivity is present independent of clinical GVHD. High relapse rates caused by T cell depletion may be counterbalanced by the induction of GVL in these patients.
One of the arguments against pre-emptive DLI may be the risk of exposing patients to GVHD who otherwise would not have suffered from this potentially life-threatening complication. Especially in CML patients whose relapse can be detected early and high-dose DLI has proven to be very effective in overt relapse, one could argue against pre-emptive DLI. However, CML patients transplanted in the chronic phase may relapse subsequently in accelerated phase or in blast crisis. DLI has been shown to be less effective in these patients. Even if DLI is given during early relapse 10 to 20% of patients do not respond to DLI. 47 In these patients the donor T cells may not recognize leukemia-specific target antigens on the cell surface or may be rejected early after infusion by autologous T cells that have survived after BMT or that are part of the malignant clone. 48, 49 In relapsed AML and especially ALL, DLI is only effective in a minority of patients. 20, 45, 50, 51 Pre-emptive DLI are administered during clinical, hematologic, cytogenetic, and/or molecular remission of the disease. The number of residual tumor cells, if present, is relatively low, chimerism is predominantly of donor origin, and the immunological balance between donor cells and autologous cells is in the advantage of donor cells. These circumstances may be optimal for additional donor lymphocytes to exert their GVL reactivity even in hematological malignancies, such as ALL that usually do not respond to DLI when relapse has occurred.
In the present analysis, we show that the incidence and severity of GVHD after pre-emptive DLI is low when using 0.1 × 10 8 CD3 + cells/kg b.w. Five out of seven patients who had grade 1 acute GVHD after BMT did not develop GVHD after DLI. We are now considering giving DLI also to patients with acute GVHD grade 2 that has resolved after a short course of additional immunosuppression. The majority of patients with acute GVHD in the non-DLI group had grade 2 GVHD and consequently they were included in the non-DLI group. These patients may also benefit from this pre-emptive immunotherapy without developing life-threatening GVHD.
In our study, four patients relapsed or already had progressive disease before they were eligible for DLI. Three of these patients showed only GVHD grade 1 of the skin after BMT that disappeared within 6 weeks after BMT. One patient had no GVHD at all. Currently, we taper all immunosuppressive drugs earlier after BMT to provoke GVL in these patients. If no GVHD or reactivation of GVHD occurs after cessation of these drugs, we treat the patients with pre-emptive DLI.
One of the major problems after high-dose DLI that is given for overt relapse is aplasia, which develops in up to 50% of responders to this therapy and contributes significantly to mortality. The development of aplasia in patients who relapse after BMT is at least partly dependent on residual donor hematopoiesis at the time of lymphocyte infusion. 18, 52, 53 Since preemptive DLI is given at the moment of nearly complete or complete donor hematopoiesis, aplasia is not expected as we observed in our patients. Only a minority of patients (26%) had mixed chimerism at the time of DLI and in the patients who had mixed chimerism the majority of the cells was of donor origin. Sequential monitoring chimerism after BMT showed that the patients in the DLI group needed more time to establish complete donor chimerism. The number of patients that had mixed chimeras at 6 months after BMT (26%) was slightly higher than in the control group (19%). The higher incidence and severity of GVHD in the control group may have contributed to a lower number of mixed chimeras. Surprisingly, the GVL reactivity in these patients was ultimately less effective in preventing relapse than that in the patients who received pre-emptive DLI. Despite the higher incidence of severe GVHD in the non-DLI group, the relapse rate was significantly higher in this group. This somewhat paradoxical result may be caused by the intensive and prolonged immunosuppression given to treat GVHD leading to early suppression of the GVL effect.
The relapse rate among CML patients was quite different between the two groups and appears to account for much of the difference in outcomes observed between the two groups. If we exclude the CML patients from the analysis, the number of non-CML patients in both groups is too low to draw any conclusions with regard to relapse. The GVL effect of preemptive DLI in non-CML patients can only be demonstrated in a much larger randomized study. However, concerning the number of high risk patients in this study, the observed relapse rates were low for this category of patients transplanted with partially T cell-depleted grafts.
The ultimate goal of cellular allogeneic immunotherapy after stem cell transplantation is optimal GVL effect without severe GVHD. The optimal strategy for the amelioration of GVHD in DLI patients has yet to be defined. Several strategies are presently under investigation, such as manipulation of DLI by selective depletion of CD8 + cells, [54] [55] [56] incorporation of a suicide gene into T cells in an effort towards more specific modulate GVH/GVL activity, 57, 58 and custom-made leukemia reactive cytotoxic T lymphocytes. 59 However, these techniques are often time-consuming, labor intensive and their value has to be established.
Our data have not been obtained in a randomized prospective trial and selection bias may have influenced our results. However, the total cohort of patients consisted of consecutive transplanted patients, patients were only selected on the basis of GVHD characteristics and all patients were included in the study on the basis of intention-to-treat. An alternative control group would have been a historical matched control group. Because of changes in conditioning regimen and advances in supportive care we did not consider a historical matched group as a representative control group. Another argument against selection bias is demonstrated by the survival and relapse curves that are almost identical in the first 9 months after BMT. A multicenter prospective randomized trial will start soon. This is the first study that shows that pre-emptive DLI in patients who had no significant GVHD after BMT and who were not on immunosuppressive therapy is feasible and results in low relapse rates in patients who are at high risk of relapse. The incidence and severity of GVHD disease after DLI is low. However, we found this to be dependent on the number of CD3 + cells administered. The results, so far, suggest that in patients who suffer from more than grade 1 acute GVHD, this early, more intensive GVHD followed by immunosuppressive therapy resulted in less GVL effect when compared to less severe GVHD followed by DLI. This category of BMT patients may also be safely treated with pre-emptive DLI to reduce relapse rate and increase leukemia-free survival after T celldepleted stem cell transplantation.
